Evidence map›Paper›PMID 25273097›Full record

ArticleScience translational medicine2014

A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation.

Marianne Delville, Tara K Sigdel, Changli Wei, Jing Li, Szu-Chuan Hsieh, Alessia Fornoni, George W Burke, Patrick Bruneval, Maarten Naesens, Annette Jackson and 6 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01331668 (Biobank Renal Transplantation University Hospitals Leuven), which is not on this map. Cited by 137 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 2 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01331668 recruitingnot on this map

Biobank Renal Transplantation University Hospitals Leuven

TypeobservationalSponsorUniversitaire Ziekenhuizen KU LeuvenRan2004 to 2099Enrolled5,000ConditionsKidney Failure
3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 2 syntheses or guidelines pooled it, 229 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Serum Factors in Primary Podocytopathies.Antibodies (Basel, Switzerland) · 2025
    Review
  12. Review
  13. Review
  14. Article
  15. Targeting B Cells and Plasma Cells in Glomerular Disease.Journal of the American Society of Nephrology : JASN · 2025
    Review
  16. Autoantibodies Targeting Proteasome Subunit Alpha Type 1 in Autoimmune Podocytopathies.Journal of the American Society of Nephrology : JASN · 2025
    Article
  17. Review
  18. Article
  19. Review
  20. Development of Non-HLA Antibodies and Their Association With Antibody-Mediated Rejection in Pediatric Kidney Transplant Recipients.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Article

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Marianne DelvilleDepartment of Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes Sorbonne Paris Cité, INSERM U1171, Réseau Thématique de Recherche et de Soins Centaure, Labex Transplantex, 75015 Paris, France.
Tara K SigdelDivision of Transplant Surgery, University of California San Francisco, San Francisco, CA 94143, USA.
Changli WeiDepartment of Medicine, Rush University Medical Center, Chicago, IL 60612, USA.
Jing LiDepartment of Medicine, Rush University Medical Center, Chicago, IL 60612, USA.
Szu-Chuan HsiehDivision of Transplant Surgery, University of California San Francisco, San Francisco, CA 94143, USA.
Alessia FornoniPeggy and Harold Katz Family Drug Discovery Center, Division of Nephrology and Hypertension, University of Miami School of Medicine, Miami, FL 33146, USA.
George W BurkeDivision of Transplant Surgery, University of Miami School of Medicine, Miami, FL 33146, USA.
Patrick BrunevalDepartment of Pathology, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France.
Maarten NaesensNephrology and Renal Transplantation, University Hospitals Leuven, 3000 Leuven, Belgium.
Annette JacksonDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Nada AlachkarDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Guillaume CanaudDepartment of Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes Sorbonne Paris Cité, INSERM U1171, Réseau Thématique de Recherche et de Soins Centaure, Labex Transplantex, 75015 Paris, France.
Christophe LegendreDepartment of Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes Sorbonne Paris Cité, INSERM U1171, Réseau Thématique de Recherche et de Soins Centaure, Labex Transplantex, 75015 Paris, France.
Dany AnglicheauDepartment of Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes Sorbonne Paris Cité, INSERM U1171, Réseau Thématique de Recherche et de Soins Centaure, Labex Transplantex, 75015 Paris, France.
Jochen ReiserDepartment of Medicine, Rush University Medical Center, Chicago, IL 60612, USA. minnie.sarwal@ucsf.edu jochen_reiser@rush.edu.
Minnie M SarwalDivision of Transplant Surgery, University of California San Francisco, San Francisco, CA 94143, USA. minnie.sarwal@ucsf.edu jochen_reiser@rush.edu.
Rush University Medical Center · USJohns Hopkins Medicine · USJohns Hopkins University · US

Funding

Miami Clinical and Translational Science InstituteUL1TR000460 · NCATS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SACCO, RALPH L. · 2012 to 2016
$16.9M
Novel Therapies to Modulate the Inflammatory Alloresponse in Renal GraftsU01AI113362 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VINCENTI, FLAVIO · 2014 to 2023
$15.2M
Role of Circulating suPAR in FSGSR01DK101350 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI REISER, JOCHEN · 2013 to 2017
$2.6M
Proteolytic Regulation of Podocyte Function by Cathepsin L.R01DK073495 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI REISER, JOCHEN · 2006 to 2015
$2.4M
Urinary Proteome Monitoring for Transplant InjuryR01DK083447 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CAMP, DAVID G, SARWAL, MINNIE M · 2010 to 2013
$2.4M
Novel Targets of Rituximab in FSGSR01DK090316 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI FORNONI, ALESSIA · 2011 to 2015
$1.7M
Glomerular Disease Mechanisms mediated by Podocyte TRPC6R01DK089394 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI REISER, JOCHEN · 2010 to 2014
$1.6M
Transplant injury biology and monitoring by urine proteomicsR56DK083447 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SARWAL, MINNIE M · 2015 to 2015
$100k
NCATS NIH HHS 1UL1TR000460NCATS NIH HHS UL1 TR000460NIAID NIH HHS U01 AI113362NIAID NIH HHS U01AI113362NIDDK NIH HHS DK090316NIDDK NIH HHS DK101350NIDDK NIH HHS R01 DK073495NIDDK NIH HHS R01 DK083447NIDDK NIH HHS R01 DK089394NIDDK NIH HHS R01 DK090316NIDDK NIH HHS R01 DK101350NIDDK NIH HHS R56 DK083447PHS HHS 5U24DX076169
6 · The paper itself

Abstract

Recurrence of focal segmental glomerulosclerosis (rFSGS) after kidney transplantation is a cause of accelerated graft loss. To evaluate pathogenic antibodies (Abs) in rFSGS, we processed 141 serum samples from 64 patients with and without primary rFSGS and 34 non-FSGS control patients transplanted at four hospitals. We screened about 9000 antigens in pretransplant sera and selected 10 Abs targeting glomerular antigens for enzyme-linked immunosorbent assay (ELISA) validation. A panel of seven Abs (CD40, PTPRO, CGB5, FAS, P2RY11, SNRPB2, and APOL2) could predict posttransplant FSGS recurrence with 92% accuracy. Pretransplant elevation of anti-CD40 Ab alone had the best correlation (78% accuracy) with rFSGS risk after transplantation. Epitope mapping of CD40 with customized peptide arrays and rFSGS sera demonstrated altered immunogenicity of the extracellular CD40 domain in rFSGS. Immunohistochemistry of CD40 demonstrated a differential expression in FSGS compared to non-FSGS controls. Anti-CD40 Abs purified from rFSGS patients were particularly pathogenic in human podocyte cultures. Injection of anti-CD40/rFSGS Ab enhanced suPAR (soluble urokinase receptor)-mediated proteinuria in wild-type mice, yet no sensitizing effect was noted in mice deficient in CD40 or in wild-type mice that received blocking Ab to CD40. In conclusion, a panel of seven Abs can help identify primary FSGS patients at high risk of recurrence before transplantation. Intrarenal CD40 (and possibly other specific glomerular antigens) is an important contributor to FSGS disease pathogenesis. Human trials of anti-CD40 therapies are warranted to evaluate their efficacy for preventing rFSGS and improving graft survival.

Indexed as

Kidney TransplantationAdultAntibodiesCase-Control StudiesCD40 AntigensEnzyme-Linked Immunosorbent AssayFemaleGlomerulosclerosis, Focal SegmentalHumansMaleRecurrenceAntibodiesCD40 Antigens

Identifiers

PMID25273097
PMCPMC4394366
OpenAlexW1995585467

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.